WA
NBIX icon

Winfield Associates’s Neurocrine Biosciences NBIX Stock Holding History

Winfield Associates’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-15
Closed -$2K – 450
2017
Q4 		$2K Hold
15
– – ﹤0.01% 680
2017
Q3 		$1K Hold
15
– – ﹤0.01% 705
2017
Q2 		$1K Hold
15
– – ﹤0.01% 798
2017
Q1 		$1K Buy
+15
New +$643 ﹤0.01% 683

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Winfield Associates's NBIX Position: Q1 2018 in Review

Winfield Associates sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 15 shares — an estimated $2K sold.

Winfield Associates first reported a position in NBIX in Q1 2017 and held it in 4 quarters. The position peaked at $2K in Q4 2017. 266 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

  • Winfield Associates reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
  • Winfield Associates sold 15 Neurocrine Biosciences shares in Q1 2018, an estimated $2K.
  • Winfield Associates first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 4 quarters.
  • Winfield Associates's Neurocrine Biosciences position peaked at $2K in Q4 2017.
  • 266 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Winfield Associates's 13F filing for Q1 2018, filed 10 May 2018.